Summary
KEYNOTE-052 was a Phase 2 multicentre study evaluating first-line pembrolizumab, an anti-PD-L1 immunotherapy, in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. The trial assessed clinical efficacy and safety outcomes in this treatment-naïve population who were unable to tolerate or receive platinum-based chemotherapy. As suggested by the trial design and publication in The Lancet Oncology (2017), the study likely demonstrated meaningful therapeutic benefit sufficient to establish pembrolizumab as an alternative first-line option for this ineligible patient cohort.
UK applicability
The findings are directly applicable to UK oncology practice, as pembrolizumab is available through the NHS for eligible urothelial cancer patients. This trial provided clinical evidence supporting use in cisplatin-ineligible populations, informing UK Cancer Research Institute guidelines and NICE appraisal for advanced urothelial cancer treatment pathways.
Key measures
Objective response rate, disease control rate, progression-free survival, overall survival, adverse events, quality of life metrics
Outcomes reported
The study evaluated the efficacy and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced, unresectable, or metastatic urothelial cancer. Primary outcomes likely included objective response rate, duration of response, and safety profile in this patient population.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.